Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee.

Next Previous
Trial Profile

A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triamcinolone (Primary) ; Triamcinolone
  • Indications Musculoskeletal pain
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Flexion Therapeutics

    • Most Recent Events

    • 01 Dec 2019 Results of pooled Analysis of three Phase 2/3 Clinical Trials (NCT01487161, NCT02116972, NCT02357459) published in the Pain and Therapy
    • 08 Nov 2017 Results of subgroup analysis (n=586) assessing the effectiveness of FX006 in patients with and without baseline inflammation using pooled data from three trials (NCT01487161, NCT02116972 and NCT02357459), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 02 Nov 2017 According to a Flexion Therapeutics media release, pooled analysis data of this and two other trials (see CT profiles 243924 and 234469) will be presented at the 2017 American College of Rheumatology (ACR) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top